MACM
CPRX

March Altus Capital Management’s Catalyst Pharmaceutical CPRX Stock Holding History

March Altus Capital Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-80,890
Closed -$334K – 18
2015
Q2 		$334K Buy
+80,890
New +$322K 1.94% 19

Other funds holding CPRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

March Altus Capital Management's CPRX Position: Q3 2015 in Review

March Altus Capital Management sold out of Catalyst Pharmaceutical (CPRX) in Q3 2015, closing a stake of 80,890 shares — an estimated $334K sold.

March Altus Capital Management first reported a position in CPRX in Q2 2015 and held it in 1 quarter. The position peaked at $334K in Q2 2015. 90 funds tracked by Wall St. Rank hold CPRX as of Q3 2015.

  • March Altus Capital Management reported no remaining Catalyst Pharmaceutical position as of Q3 2015 after selling out during the quarter.
  • March Altus Capital Management sold 80,890 Catalyst Pharmaceutical shares in Q3 2015, an estimated $334K.
  • March Altus Capital Management first reported a position in Catalyst Pharmaceutical in Q2 2015 and held it in 1 quarter.
  • March Altus Capital Management's Catalyst Pharmaceutical position peaked at $334K in Q2 2015.
  • 90 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2015.

Based on March Altus Capital Management's 13F filing for Q3 2015, filed 16 Nov 2015.